Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALSGlobeNewsWire • 11/13/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/09/19
Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and Recent Business Highlights on November 6, 2019GlobeNewsWire • 10/15/19
Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)GlobeNewsWire • 09/30/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/11/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/15/19